Regeneron Pharmaceuticals

The drug combination from Regeneron Pharmaceuticals cut patient deaths from 30% to 24% among those who hadn’t already developed an immune response against COVID-19.

Regeneron says tests in more than 4,000 recently diagnosed patients found its two-antibody combo drug cut the risk of hospitalization or death by 70%.

The drug is a combo of two antibodies to enhance the chances it will prove effective. It's an experimental medicine that President Trump was given when he was sickened last month.